Repro-Med Systems Posts Record Quarter, Reaffirms Outlook

Repro-Med Systems, Inc. ((KRMD)) has held its Q1 earnings call. Read on for the main highlights of the call.

Repro-Med Systems, Inc. opened its latest earnings call on an upbeat note, highlighting record revenue, accelerating pharma-service growth and expanding international demand. Management acknowledged some pressure on margins and rising operating costs but emphasized disciplined cash usage, near-breakeven profitability and a growing pipeline, framing the quarter as evidence that strategic investments are starting to pay off.

Record Revenue and Strong Top-Line Growth

Repro-Med reported first-quarter fiscal 2026 revenue of $11.8 million, a 22% year-over-year increase and the highest quarterly sales in its history. Management credited the performance to recurring revenue from approximately 60,000 patients on the KORU platform, underscoring the stickiness of its home infusion franchise.

Domestic and International Core Growth

The company’s core domestic business grew 12% year over year, helped by new patient starts and wins from competitors. International core revenue rose an even faster 35%, driven by prefilled syringe conversions and strong distributor orders in key European Union markets despite some variability in order timing.

Clinical Trial and PST Revenue Surge

Pharma and clinical trial revenue, referred to as PST, jumped 166% from a year earlier as partners increased product orders. This surge reflects advancing collaborations with drug developers that are using KORU’s devices to support late-stage clinical programs and potential commercial launches.

Profitability and Cash Discipline Progress

Adjusted EBITDA was essentially breakeven at a loss of just $10,000, representing a 95% improvement from the prior year as scale benefits began to flow through. Net loss narrowed by one-third to $800,000, while cash usage in the quarter was limited to $0.1 million, leaving $8.8 million on the balance sheet.

Advancing Non-Ig Pipeline and Regulatory Progress

The company reported that two non-Ig collaborations advanced to Phase III, including Empaveli for a fourth indication and another partner resuming a late-stage trial. Management also filed a 510(k) submission for its Freedom Infusion System with deferoxamine and highlighted eight active non-Ig opportunities that together represent more than 6 million potential annual infusions.

Product and Market Expansion Milestones

Repro-Med secured EU MDR clearance for its Freedom60 system with prefilled syringe compatibility, opening additional European growth channels. The company is also rolling out RYSTIGGO under a new label, engaging with regulators on a Phesgo 510(k) and developing a next-generation Freedom60 pump aimed at regulatory filings in 2026.

Strategic Leadership Transition

A leadership change is underway, with Adam Kalbermatten slated to become chief executive on July 1, and the board presented the shift as a planned evolution rather than a reset. Executives reiterated confidence in the existing strategy and long-term goals of reaching $100 million in revenue, gross margins above 65% and EBITDA margins above 20%.

Gross Margin Pressure

Gross margin slipped to 61.5% in the quarter from 62.8% a year ago, a 130-basis-point decline that partially stemmed from tariffs and the timing of production runs. Management estimated that tariff-related charges alone accounted for about 87 basis points of the drop, framing the impact as a discrete but meaningful drag on profitability.

Operating Expense Increase

Operating expenses rose 11% year over year as the company continued to invest in sales, marketing and research and development. Management argued that these costs are necessary to support long-term growth, while also signaling a focus on operating leverage to prevent spending from outpacing revenue over time.

Cash Seasonality and Second-Quarter Headwind

Despite minimal cash burn in the first quarter, Repro-Med warned that the second quarter will be its heaviest cash-usage period due to annual bonus payments. The company nonetheless expects cash trends to improve in the second half, pointing to a stronger revenue base and tighter control of discretionary spending.

Adjusted EBITDA Still Slightly Negative

Even with significant improvement, adjusted EBITDA remained slightly negative in the quarter, underscoring that full profitability has not yet been achieved. Management framed this as a near-term issue, highlighting the trajectory of margins and the expectation that higher volumes and cost controls will push the metric into positive territory.

International Variability and Distributor Dynamics

Executives cautioned that international growth can be uneven by country because of distributor ordering patterns and stocking cycles. Strong pump orders may create short-term spikes in revenue, while subsequent consumable demand could lag, making quarterly trends less predictable even when underlying adoption remains healthy.

Tariff and Production Timing Impacts

Tariff-related charges and the timing of production runs late last year combined to raise costs and weigh on margins in the current quarter. Management characterized these factors as one-time or timing-related headwinds rather than structural issues, suggesting some relief in future periods if trade conditions stabilize.

Pipeline Pruning and Modest Near-Term Non-Ig Revenue

The company removed vancomycin from its active pipeline, citing both risk considerations and limited incremental revenue potential from that program. Looking ahead, management expects individual new-label non-Ig drugs to contribute modestly in the near term, roughly $0.5 million to $1 million in total revenue for 2026 as they ramp gradually.

Geopolitical Risk Exposure

Management noted exposure to geopolitical risk through a distributor relationship in the Middle East, cautioning that regional conflict could affect order patterns. While this channel does not yet represent a significant share of revenue, it introduces uncertainty and may contribute to softer demand or delayed purchasing decisions.

Outlook and Forward Guidance

Repro-Med reaffirmed its full-year fiscal 2026 outlook for revenue between $47.5 million and $50 million, implying 15% to 22% growth. The company also maintained targets for gross margins of 61% to 63%, positive adjusted EBITDA and positive cash flow for the year, and reiterated longer-term ambitions for sustained double-digit growth and stronger profitability metrics.

Repro-Med’s latest earnings call painted a picture of a company gaining momentum, with record revenue, surging clinical trial activity and expanding international reach offsetting temporary margin and cash-flow headwinds. Investors will be watching how quickly management can translate near-breakeven results into durable profitability, but the reiterated guidance and deepening pipeline suggest the strategic direction remains intact.